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Introduction {#ss1}
============

Influenza is a significant cause of paediatric morbidity and mortality. Between 2002 and 2005, the annual rate of hospitalisations coded as influenza among Australian children aged 0--4 years was 82·1/100,000, higher than any other age group.[^1^](#b1){ref-type="ref"} In Western Australia (WA) using population‐based data linkage for the period 1990--2000, we reported an annual influenza hospitalisation rate of 160/100 000 for non‐Aboriginal children and 640/100 000 for Aboriginal children aged \<2 years.[^2^](#b2){ref-type="ref"}

A systematic review has shown influenza vaccine effectiveness (VE) was 59% (95% CI 41--71%) in preventing confirmed influenza in healthy children aged 2--16 years,[^3^](#b3){ref-type="ref"} but there is a paucity of data of VE in children under of 2 years of age. Reflecting the burden of influenza and the accepted protective effect of vaccination, the Advisory Committee on Immunisation Practices in the United States of America recommended the use of influenza vaccine in children aged 6--23 months in 2002[^4^](#b4){ref-type="ref"} and expanded the recommendation to those aged 6--59 months in late 2006.[^5^](#b5){ref-type="ref"}

In response to a cluster of childhood deaths related to influenza virus A infection in WA in 2007[^6^](#b6){ref-type="ref"} and the burden of influenza in young children, influenza vaccine was provided free of charge for all WA children aged 6--59 months in 2008. We commenced the Western Australian Influenza Vaccine Effectiveness (WAIVE) study in 2008 to determine whether there is a direct protective effect of inactivated influenza vaccine in young children.

The WAIVE study is a series of observational studies measuring VE in three different patient settings: general practice, the emergency department and hospital inpatients. Here, we report on a nested case--control study using prospective incidence density case sampling and matched control sampling for hospital inpatients where controls were hospitalised for a non‐respiratory diagnosis. We discuss the methodological issues of conducting such a study and report interim VE point estimates following the first year of the programme.

Methods {#ss2}
=======

We estimated influenza VE against laboratory‐confirmed influenza in children aged 6--59 months admitted to five metropolitan Perth hospitals. We defined all children admitted to hospital with laboratory‐confirmed influenza as cases and selected children admitted to hospital for an acute non‐respiratory illness during the influenza season as controls. Controls were matched for age (6--12 months, 1--2 years, 3--4 years and 4 to \<5 years) and Aboriginal/Torres Strait Islander status. Cases admitted with laboratory‐confirmed influenza were identified from hospital admission lists, laboratory reports and from notifications to the Communicable Disease Control Directorate of the WA Department of Health. Screening for cases occurred at Princess Margaret Hospital for Children, WA's tertiary paediatric hospital and five peripheral hospitals within metropolitan Perth. It is a routine procedure for all paediatric inpatients presenting with a respiratory and/or febrile illness to have a per‐nasal aspirate for virus identification testing.

Potential controls with a non‐respiratory illness were identified from hospital admission lists. For each case, we aimed at recruiting two controls admitted to hospital within a week of the case's admission. Following informed consent, parents were given a questionnaire to complete, which included their child's demographic data, influenza vaccinations received in 2008 and previous years and any underlying chronic illnesses. Vaccine status was validated for 87% of all participants with the child's vaccine provider or via the Australian Childhood Immunisation Register. Children were excluded if they had a known contraindication to influenza vaccine,[^7^](#b7){ref-type="ref"} a known immunodeficiency disorder (including human immunodeficiency virus (HIV) infection), current or recent immunosuppressive treatment or administration of immunoglobulins in the previous 3 months.

CSL Biotherapies provided Fluvax™ and Sanofi Pasteur Ltd provided Vaxigrip™, both trivalent inactivated influenza vaccines (TIV), formulated as 0·5‐ml pre‐filled syringes containing 15‐μg haemagglutinin of each of the three recommended vaccine strains for children ≥ aged 3 years to ≤5 years. Fluvax Junior™ and Vaxigrip Junior™, both formulated as 0·25‐ml pre‐filled syringes containing 7·5‐μg haemagglutinin of each of the vaccine strains, were provided for children ≥ aged 6 months to \<3 years. Children who received other licensed influenza vaccines were eligible for inclusion in the study.

Cases and controls were defined as fully vaccinated according to the National Health and Medical Research Council Immunisation Handbook[^8^](#b8){ref-type="ref"} if they had received 2 age‐appropriate doses of TIV at least 21 days apart and more than 14 days prior to ILI onset in 2008. Children who had received at least two previous doses of influenza vaccine in any year were also defined as fully vaccinated if they received one dose of the age‐appropriate vaccine in 2008. Children who received one or more doses of vaccine in any previous year but no vaccine in 2008 were counted as unvaccinated.

Per‐nasal aspirates collected from hospital inpatients and were tested for antigens to influenza and other common respiratory viruses using a standard direct immunofluorescence method and were cultured on LLC‐MK2 cells using centrifuge‐enhanced inoculation and detection by monoclonal antibodies. Samples negative for influenza by these tests were then tested by a real‐time polymerase chain reaction (PCR) assay directed at the matrix gene of influenza A or influenza B using previously published primers.[^9^](#b9){ref-type="ref"} Samples that were culture positive were referred to the World Health Organization Collaborating Centre for Influenza Reference and Research in Melbourne, where detailed antigenic characterisation was performed.

Differences in categorical variables were tested by the Chi‐squared test or Fisher's exact test. Using laboratory‐confirmed influenza as the primary outcome and vaccination status as the primary exposure, adjusted ORs and 95% confidence intervals (CIs) were calculated using multivariate conditional logistic regression models comparing fully vaccinated children with unvaccinated children including, sex, presence of comorbidities (yes/no) and pre‐term birth as covariates. VE was calculated as 1 -- OR. Data analysis was conducted in SAS version 9 (SAS Institute Inc., Cary, NC, USA). Ethical approval for the study was obtained from the ethics committees of Princess Margaret Hospital for Children, the Joondalup Health Campus, the South Metropolitan Area Heath Service and the Western Australian Aboriginal Health Information and Ethics Committee.

Results {#ss3}
=======

The influenza season in 2008 commenced at the end of July and continued through mid November and was dominated by influenza virus B with an unusually late peak. Antigenic typing at the World Health Organisation Collaborating Centre identified the circulating strains in WA as A/Solomon Islands/3/2006‐like (H1N1), A/Brisbane/59/2007‐like (H1N1), A/Brisbane/10/2007‐like (H3N2) and a mixture of viruses from the two B lineages, B/Yamagata and B/Victoria. Circulating strains matched the vaccine strains for both influenza A subtypes and for viruses of the B/Yamagata lineage, represented in the vaccine by B/Florida.

Thirty‐five hospitalised children with laboratory‐confirmed influenza were deemed eligible. Of these, 26 children (74%) were included, eight were unable to be contacted and one with a hospital acquired infection was excluded ([Figure 1](#f1){ref-type="fig"}). There were 10 cases of influenza A infection (five H1N1, three H3N2 and two untyped) and 16 cases with influenza B. All but two cases were admitted to Princess Margaret Hospital for Children. We recruited 50 matched controls. Eight children (11%) identified as Aboriginal and/or Torres Strait Islander. Compared with controls, a greater proportion of cases were boys (*P* = 0·04), but there were no other significant differences between cases and controls for any other covariates ([Table 1](#t1){ref-type="table-wrap"}). The proportion of children in the study who were fully vaccinated was 22%, with a higher proportion of controls (30%) vaccinated compared to cases (7%). The adjusted estimate of VE comparing fully vaccinated with unvaccinated children was 83% (95% CI −54 to 98). The VE estimate was similar prior to adjusting for covariates (VE 87%, 95% CI −11 to 98). All cases of influenza A were unvaccinated, and the two cases of influenza B in fully vaccinated children were caused by strains of the mismatched B/Victoria lineage. One child admitted with laboratory‐confirmed influenza had only 1 dose of TIV and was excluded from the analysis.

![ Schematic representation of WAIVE study design for hospitalised patients.](IRV-4-231-g001){#f1}

###### 

 Case and control comparison from 76 hospital inpatients

  Co‐variate                 Cases (%)   Controls (%)   *P*    \% fully vaccinated   *P*
  -------------------------- ----------- -------------- ------ --------------------- ------
  Age (years)                                                                        
   ≤2                        12 (46)     24 (48)        0·88   20                    0·60
   \>2                       14 (54)     26 (52)        25                           
  Sex                                                                                
   Female                     8 (31)     28 (56)        0·04   25                    0·60
   Male                      18 (69)     22 (44)        20                           
  ATSI^\*^                                                                           
   Yes                        3 (12)      5 (10)        0·84   13                    0·48
   No                        23 (88)     45 (90)        24                           
  Gestation (weeks)                                                                  
   \<38                       6 (23)     12 (24)        0·93   11                    0·19
   ≥38                       20 (77)     38 (76)        26                           
  Comorbid condition^\*\*^                                                           
   Present                    3 (12)      6 (12)        0·95   23                    0·95
   Absent                    23 (88)     44 (88)        22                           

^\*^Identification as Aboriginal and/or Torres Strait Islander.

^\*\*^Comorbid conditions included all chronic diseases for which influenza vaccine is recommended in Australia: cardiac disease, asthma, chronic respiratory conditions, chronic neurological disorders or other chronic illnesses requiring regular medical follow‐up or hospitalisation.

Discussion {#ss4}
==========

For the first time in any Australian state, influenza vaccine was recommended and provided free of charge for all children in WA aged 6--59 months in 2008. We estimated the protection from hospitalised laboratory‐confirmed influenza afforded to vaccinated children through a case--control study with controls hospitalised for a non‐respiratory illness. Our interim VE estimate was high, although patient numbers were too low for this estimate to be statistically significant. In this first year of the study, we identified important methodological issues with control selection.

We chose a nested case--control design with controls having no respiratory symptoms. However, matching cases to controls was problematic. We found it difficult to recruit sufficient numbers of matched controls in a timely manner as very few hospitalised children had no respiratory symptoms during the peak of the influenza season. Moreover, young children are admitted for only a few days so that many potential controls had been discharged before they could be recruited, and it was necessary to complete enrolment and data collection by telephone. For future years, we will use an alternative approach to control selection where children admitted to hospital with respiratory symptoms but found to be influenza negative by laboratory testing. Matching of cases and controls will not be undertaken. This will dramatically increase the pool of patients from which controls can be selected. This so‐called test‐negative design has been used elsewhere for community‐based studies of influenza VE[^10^](#b10){ref-type="ref"}, [^11^](#b11){ref-type="ref"} and has recently been modelled by Orenstein and colleagues.[^12^](#b12){ref-type="ref"} As far as we are aware, application of this approach to estimating influenza VE in hospitalised patients would be novel.

We will concentrate on recruiting cases and controls only from Princess Margaret Hospital for Children. Screening for cases in peripheral metropolitan hospitals was labour intensive and only yielded two cases. Despite a low incidence of influenza in hospitalised young children in the first year of the study, we have demonstrated a non‐significant protective effect of vaccination. Improvement to the methodology of control selection should allow us to improve the accuracy of VE estimates in future years.
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